Eu Yan Sang

From Traditional Medicine to Big Business: Eu Yan Sang Acquisition Sparks Buzz

Rohto and Mitsui join forces to acquire Eu Yan Sang for $695M, marking a significant move in the health industry!

Eu Yan Sang, a renowned name in traditional Chinese medicine, has recently made headlines with the news of its acquisition by a consortium led by Rohto and Mitsui. The acquisition, valued at a staggering $695 million, saw the consortium taking control of an 86% stake previously held by Righteous Crane Holding (RCH). RCH, an investment holding company, is under the ownership of Tower Capital Asia, a subsidiary known for its strategic investments in various sectors.

The acquisition of Eu Yan Sang, a well-established player in the health and wellness market, by Rohto and Mitsui reflects a strategic move towards expanding their presence in the traditional medicine industry. This bold step not only signifies a shift in the landscape of the health sector but also underlines the growing interest in alternative healing practices.

Eu Yan Sang's legacy in traditional Chinese medicine dates back to its inception in the 1870s, making it a pioneer in combining ancient remedies with modern healthcare solutions. The brand's reputation for quality and authenticity has garnered a loyal customer base over the years, positioning it as a trusted name in the industry.

As Rohto and Mitsui take the reins of Eu Yan Sang, the future holds exciting possibilities for the brand's evolution and expansion. This acquisition not only marks a significant milestone in the company's journey but also sets the stage for innovative collaborations and developments in the realm of traditional medicine.